MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.
The current price of MBQIF is $0.86 USD — it has decreased by -3.21% in the past 24 hours. Watch MindBio Therapeutics stock price performance more closely on the chart.
What is MindBio Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MindBio Therapeutics stocks are traded under the ticker MBQIF.
When did MindBio Therapeutics complete a stock split?▼
MindBio Therapeutics has not had any recent stock splits.
Where is MindBio Therapeutics headquartered?▼
MindBio Therapeutics is headquartered in Vancouver, DE.